Table 1 Demographic, clinical and laboratory data of the studied subjects
From: Malondialdehyde and superoxide dismutase levels in patients with epilepsy: a case–control study
Epileptic group (n = 62) | Controls group (n = 62) | test | p | |||
|---|---|---|---|---|---|---|
Age (years) | ||||||
Mean ± SD | 27.98 ± 6.44 | 26.63 ± 6.06 | t = 1.207 | 0.230 | ||
Range | 18.0–43.0 | 19.0–39.0 | ||||
Sex | No | % | No | % | ||
Male | 36 | 58.1 | 35 | 56.5 | χ2 = 0.033 | 0.856 |
Female | 26 | 41.9 | 27 | 43.5 | ||
Age of onset | ||||||
Mean ± SD | 17.85 ± 4.64 | – | ||||
Disease duration (years) | ||||||
Mean ± SD | 13.11 ± 8.19 | – | ||||
Seizure type | No | % | ||||
Focal | 21 | 33.9 | – | |||
Generalized | 41 | 66.1 | – | |||
Seizure control | No | % | ||||
Controlled | 26 | 41.9 | – | |||
Uncontrolled | 36 | 58.1 | – | |||
Seizure frequency of uncontrolled patients | No | % | ||||
More than once /month | 10 | 27.8 | – | |||
Once/ 1–2 months | 14 | 38.9 | – | |||
Once/ 3–4 months | 7 | 19.4 | – | |||
Once/ 5–6 months | 5 | 13.9 | – | |||
Type of therapy | No | % | ||||
Monotherapy | 27 | 43.5 | – | |||
Polytherapy | 35 | 56.5 | – | |||
MDA (nmol/ml) | ||||||
Mean ± SD | 5.83 ± 1.46 | 4.80 ± 0.62 | 5.075 | < 0.001* | ||
SOD (U/ml) | ||||||
Mean ± SD | 7.59 ± 0.85 | 11.98 ± 1.39 | 21.228 | < 0.001* | ||